Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version

Bimal Bhindi¹, Ronald Kool², Girish S Kulkarni³, D Robert Siemens⁴, Armen G Aprikian², Rodney H Breau⁵, Fadi Brimo⁶, Adrian Fairey⁷, Christopher French⁸, Nawar Hanna⁹, Jonathan I Izawa¹⁰, Louis Lacombe¹¹, Victor McPherson², Ricardo A Rendon¹², Bobby Shayegan¹³, Alan I So¹⁴, Alexandre R Zlotta¹⁵, Peter C Black¹⁴, Wassim Kassouf²

Affiliations

¹ Section of Urology, Department of Surgery, University of Calgary, Calgary, AB, Canada.
² Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
³ Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
⁴ Department of Urology, Queen's University, Kingston, ON, Canada.
⁵ Division of Urology, University of Ottawa, Clinical Epidemiology, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
⁶ Department of Pathology, McGill University Health Centre, Montreal, QC, Canada.
⁷ Division of Urology, University of Alberta, Edmonton, AB, Canada.
⁸ Division of Urology, Department of Surgery, Memorial University of Newfoundland, St. John's, NL, Canada.
⁹ Department of Urology, Université de Montréal, Montreal, QC, Canada.
¹⁰ Department of Surgery, Division of Urology, Western University, London, ON, Canada.
¹¹ Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC, Canada.
¹² Department of Urology, Dalhousie University, Halifax, NS, Canada.
¹³ Division of Urology, McMaster University, Hamilton, ON, Canada.
¹⁴ Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
¹⁵ Division of Urology, Department of Surgery, Sinai Health System and Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.

PMID: 35099374
PMCID: PMC8418252
DOI: 10.5489/cuaj.7487

Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version

Bimal Bhindi et al. Can Urol Assoc J. 2021 Aug.

. 2021 Aug;15(8):230-239.

doi: 10.5489/cuaj.7487.

Authors

Affiliations

¹ Section of Urology, Department of Surgery, University of Calgary, Calgary, AB, Canada.
² Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
³ Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
⁴ Department of Urology, Queen's University, Kingston, ON, Canada.
⁵ Division of Urology, University of Ottawa, Clinical Epidemiology, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
⁶ Department of Pathology, McGill University Health Centre, Montreal, QC, Canada.
⁷ Division of Urology, University of Alberta, Edmonton, AB, Canada.
⁸ Division of Urology, Department of Surgery, Memorial University of Newfoundland, St. John's, NL, Canada.
⁹ Department of Urology, Université de Montréal, Montreal, QC, Canada.
¹⁰ Department of Surgery, Division of Urology, Western University, London, ON, Canada.
¹¹ Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC, Canada.
¹² Department of Urology, Dalhousie University, Halifax, NS, Canada.
¹³ Division of Urology, McMaster University, Hamilton, ON, Canada.
¹⁴ Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
¹⁵ Division of Urology, Department of Surgery, Sinai Health System and Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.

PMID: 35099374
PMCID: PMC8418252
DOI: 10.5489/cuaj.7487

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Bhindi has been an advisory board member for Bayer and Janssen; and has received speaker honoraria from Merck. Dr. Kulkarni has been an advisory board member for Astellas, Ferring, Janssen, Merck, Roche, and Theralase; has received grants and/or honoraria from Abbvie, Ferring, Sanofi, and TerSera; and has participated in clinical trials supported by Merck, Astra Zeneca, Bristol Myers Squibb, Janssen, and Theralase. Dr. Siemens has participated in clinical trials supported by Astellas, Merck, and Pfizer. Dr. Aprikian has been an advisory board member for Abbvie, Astellas, and Bayer; and has received grants and/or honoraria from Abbvie, Astellas, Bayer, Sanofi, and TerSera. Dr. Hanna has received honoraria from Astellas and Bayer; and has participated in clinical trials supported by Merck. Dr. Izawa has received honoraria from Abbvie. Dr. McPherson has been an advisory board member for Abbvie and TerSera; has received travel funding from TerSera; and has participated in clinical trials supported by Bristol-Myers Squibb and Pfizer. Dr. Rendon has been an advisory board member for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, and Sanofi; a speakers’ bureau member for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, and Sanofi; has received grants and/or honoraria from Abbvie, Astellas, Bayer, Ferring, Janssen, and Sanofi; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bayer, Bavarian Nordic, Ferring, Janssen, Myovant, and Sanofi. Dr. Shayegan has been an advisory board member for AbbVie, Astellas, Bayer, Ferring Janssen, Knight, Merck, Pfizer, Sanofi, and TerSera; and has participated in clinical trials supported by Ipsen, Janssen, Merck, Myovant, and Pfizer. Dr. So has been an advisory board member for Abbvie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Zlotta has been an advisory board member for AstraZeneca, Ferring, Janssen, Merck, Sanofi, and Verity. Dr. Black has been an advisory board member for AbbVie, Asieris, Astellas, AstraZeneca, Bayer, Biosyent, BMS, EMD-Serono, Ferring, Fergene, H3-Biomedicine, Janssen, Merck, Protara Therapeutics, Roche, Sanofi, and Urogen; a speakers’ bureau member for AbbVie, Biosyent, Ferring, Janssen, Pfizer, and TerSera; has received payment from Bayer and Sanofi; has received grants and/or honoraria from iProgen; holds a patent marketed by Decipher Biosciences; and has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Genentech, Janssen, MDx Health, Pacific Edge, and Therelase. Dr. Kassouf has been an advisory board member for EMD Serono and Pfizer; has received grants and/or honoraria from Abbvie, Astellas, BMS, Ferring, Janssen, Merck, Roche, and Sesen Bio; and has participated in clinical trials supported by Astra Zeneca, BMS, Janssen, Pfizer, Roche, Sesen Bio, and Theralase.

Figures

**Fig. 1**
Flow chart. *Modified from Chehroudi et al. BCG: bacillus de Calmette-Guérin; CIS: carcinoma in situ; GEM: gemcitabine; HG: high-grade; Ind: induction; LG: low-grade; LVI: lymphovascular invasion; MMC: mitomycin-C; RC: radical cystectomy; SIC: single instillation of chemotherapy; TURBT: transurethral resection of bladder tumor.

See this image and copyright information in PMC

References

1. Amin M, Edge S, Greene F, et al. AJCC Cancer Staging Manual. Springer; 2017. - DOI
1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. doi: 10.1136/bmj.39489.470347.AD. - DOI - PMC - PubMed
1. Kassouf W, Traboulsi SL, Kulkarni GS, et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2015;9:E690–704. doi: 10.5489/cuaj.3320. - DOI - PMC - PubMed
1. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–77. doi: 10.1016/j.eururo.2005.12.031. - DOI - PubMed
1. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting non-muscle-invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: The CUETO scoring model. J Urol. 2009;182:2195–203. doi: 10.1016/j.juro.2009.07.016. - DOI - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version

Affiliations

Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version

Authors

Affiliations

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources